Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
665 clinical trials found
Clinical trials

ATLAS 001

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis (NCT06052059)

Currently recruiting

ATLAS 008

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease (NCT06430801)

Currently recruiting

ATRIUM

A Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid Tumors and Hematological Malignancies (NCT05338346)

No longer recruiting

Ava FIRST

Avatrombopag plus up Front ImmunosuppReSsive Therapy in treatment-naive severe aplastic anaemia (AA) – Ava FIRST- a Bayesian Optimal Phase II study (ACTRN12619001042134)

Currently recruiting

Ava NEXT

Avatrombopag in Relapsed or Refractory severe Aplastic Anaemia as EXtra Therapy - Ava NEXT– a Bayesian Optimal Phase II study (ACTRN12619001043123)

Currently recruiting

AWT020

A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients with Progressive Locally Advanced or Metastatic Cancer (NCT06092580)

Currently recruiting

AZD0305

A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of AZD0305 in Patients with Relapsed or Refractory Multiple Myeloma (NCT06106945)

Currently recruiting

B.E.A.S.T.

Full thickness Burn Wound Closure Using Bioengineered Skin: A Feasibility Study (ACTRN12623000349640)

Currently recruiting

B044426

A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, ACTIVITY, AND PHARMACOKINETICS OF GDC-6036 IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER WITH A KRAS G12C MUTATION (NCT05789082)

Currently recruiting

BAF_FRontier-1

BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor [BAFF-R] T-Cell Engager Bispecific Antibody, in Adult Participants with Previously Treated B-cell Malignancies (NCT07101328)

LY4152199 is a human BAFF-R×CD3 bispecific antibody that engages BAFF-R on the surface of B-cells and CD3 on the surface of T-cells, with the goal of T-cell-mediated elimination of BAFF-R expressing malignant B-cells. Cohort A will assess the safety, tolerability, PK, and preliminary efficacy of escalating doses of LY4152199, administered via intravenous (IV) infusion, in participants with select relapsed/refractory B-cell malignancies. Cohort B will further assess the safety, tolerability, PK, and preliminary efficacy of LY4152199 in participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
Coming soon

Baz in Men with Scz

Bazedoxifene – A New Selective Estrogen Receptor Modulator Treatment for Men with Schizophrenia: a double-blind, randomized, placebo-controlled trial (ACTRN12619001471178p)

Currently recruiting

Baz in Women with Scz

Bazedoxifene – A New Selective Estrogen Receptor Modulator Treatment for Women with Schizophrenia: a double-blind, randomized, placebo controlled trial (NCT04113993)

Currently recruiting

BCG+MM

Adding mitomycin C to BCG as adjuvant intravesical therapy for high risk, non–muscle invasive bladder cancer: A randomised phase 3 trial (ACTRN12613000513718)

Currently recruiting

BEACON-IPF

A randomised, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (NCT06097260)

No longer recruiting

BelaCarD

A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma. (ACTRN12620000490976)

Currently recruiting

Benegene

AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, LEAD-IN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY AND SAFETY DATA OF FACTOR IX OR FACTOR VIII PROPHYLAXIS REPLACEMENT THERAPY IN THE USUAL CARE SETTING OF MODERATELY SEVERE TO SEVERE ADULT HEMOPHILIA B SUBJECTS (FIX:C=2%) WHO ARE NEGATIVE FOR nAB TO AAV VECTOR-SPARK100 AND MODERATELY SEVERE TO SEVERE HEMOPHILIA A ADULT SUBJECTS (FVIII:C=1%) WHO ARE NEGATIVE FOR nAB TO AAV VECTOR SB-525 CAPSID (AAV6), PRIOR TO THE RESPECTIVE THERAPEUTIC PH 3 GENE THERAPY STUDIES (NCT03587116)

Currently recruiting

BETTER

Bevacizumab and immune chEckpoint inhibitors plus hypofractionated stereotactic radioTherapy for the treatment of sympTomatic mElanoma bRain metastases (NCT06163820)

Currently recruiting

BETTER-UAE

Prospective, Multi-Center Study using Bearing nsPVA Embolization Particles for the Treatment of uTErine fibRoids with Uterine Artery Embolization: BETTER-UAE (NCT06153667)

Currently recruiting

BG C477 101

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors (NCT06596473)

Currently recruiting

BG-C0902-101

A Phase 1a/b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C0902, an Antibody-Drug Conjugate Targeting EGFR MET, Alone and in Combination with Other Therapeutic Agents in Patients with Advanced Solid Tumors (NCT07181681)

This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. The study aims to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C0902 in participants with advanced solid tumors. The study will be conducted in 2 phases: Phase 1a (dose escalation and safety expansion) and Phase 1b (dose expansion).
Currently recruiting
3 4 5 6 7